Journal
JOURNAL OF BIOMEDICAL NANOTECHNOLOGY
Volume 11, Issue 8, Pages 1283-1311Publisher
AMER SCIENTIFIC PUBLISHERS
DOI: 10.1166/jbn.2015.2084
Keywords
Central Nervous System; Brain Tumors; Brain Drug Delivery; Blood Brain Barrier; Blood-Cerebrospinal Barrier; Nanocarrier; Active Targeting; Passive Targeting
Ask authors/readers for more resources
Epidemiological data on central nervous system disorders call for a focus on the major hindrance to brain drug delivery, blood-central nervous system barriers. Otherwise, there is little chance of improving the short-term survival of patients with diseases such as glioblastoma multiforme, which is one of the brain disorders associated with many years of life lost. Targetable nanocarriers for treating malignant gliomas are a unique way to overcome low chemotherapeutic levels at target sites devoid of systemic toxicity. This review describes the currently available targetable nanocarriers, focusing particularly on one of the newest nanocarriers, lipid nanocapsules. All of the strategies that are likely to be exploited by lipid nanocapsules to bypass blood-central nervous system barriers, including the most recent targeting approaches (mesenchymal cells), and novel administration routes (convection enhanced delivery) are discussed, together with their most remarkable achievements in glioma-implanted animal models. Although these systems are promising, much research remains to be done in this field.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available